Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma
This is an multicenter, open-label, dose-escalation study of the study drug YH004 . The study is designed to determine the safety, tolerability, maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of YH004 in subjects with advanced solid tumors and relapsed or refractory Non-Hodgkin lymphoma.
Advanced Solid Tumors|Relapsed Or Refractory Non-Hodgkin Lymphoma
DRUG: YH004
Adverse events (AEs), The safety profile of YH004 will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0., up to 1 year after the last dosing|Maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D), The MTD and/or RP2D will be determined based on the data of safety and tolerability., up to 1 year after the last dosing
This is an multicenter, open-label, dose-escalation study of the study drug YH004 . The study is designed to determine the safety, tolerability, maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of YH004 in subjects with advanced solid tumors and relapsed or refractory Non-Hodgkin lymphoma.